Comparative Pharmacology
Head-to-head clinical analysis: LETAIRIS versus TRACLEER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LETAIRIS versus TRACLEER.
LETAIRIS vs TRACLEER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Ambrisentan is an endothelin receptor antagonist that selectively inhibits endothelin-1 (ET-1) binding to endothelin type A (ETA) receptors in pulmonary vascular smooth muscle cells, reducing vasoconstriction and smooth muscle proliferation.
Bosentan is a dual endothelin receptor antagonist (ERA) that blocks endothelin-1 (ET-1) from binding to ETA and ETB receptors in pulmonary vascular smooth muscle and endothelium, reducing vasoconstriction and cell proliferation.
5 mg orally once daily, with or without food; may increase to 10 mg once daily if tolerated.
Initial: 62.5 mg twice daily orally for 4 weeks, then increase to maintenance: 125 mg twice daily orally.
None Documented
None Documented
Terminal elimination half-life is approximately 9 hours (range 6–12 hours) in healthy adults.
Terminal elimination half-life is approximately 4-5 hours in healthy adults. In patients with pulmonary arterial hypertension, half-life may be slightly prolonged (up to 6-8 hours) due to reduced clearance.
Primarily via biliary/fecal elimination (approximately 80% of metabolites and unchanged drug; ~20% renal as metabolites).
Primarily hepatic metabolism (CYP2C9 and CYP3A4) with biliary excretion of unchanged drug and metabolites. Renal excretion of unchanged drug is negligible (<1%). Fecal excretion accounts for ~75% of total clearance, with ~25% excreted in urine as metabolites.
Category C
Category C
Endothelin Receptor Antagonist
Endothelin Receptor Antagonist